ID: ALA3397807

Max Phase: Preclinical

Molecular Formula: C26H27F2NO3

Molecular Weight: 439.50

Molecule Type: Small molecule

Representations

Canonical SMILES:  COc1cccc(CN[C@@H]2CO[C@H](C(c3ccc(F)cc3)c3ccc(F)cc3)C[C@H]2O)c1

Standard InChI:  InChI=1S/C26H27F2NO3/c1-31-22-4-2-3-17(13-22)15-29-23-16-32-25(14-24(23)30)26(18-5-9-20(27)10-6-18)19-7-11-21(28)12-8-19/h2-13,23-26,29-30H,14-16H2,1H3/t23-,24-,25+/m1/s1

Standard InChI Key:  GFFCDADQFYGHCE-SDHSZQHLSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 439.50

Molecular Weight (Monoisotopic): 439.1959

AlogP: 4.41

#Rotatable Bonds: 7

Polar Surface Area: 50.72

Molecular Species: NEUTRAL

HBA: 4

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 4

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 8.29

CX LogP: 4.50

CX LogD: 3.56

Aromatic Rings: 3

Heavy Atoms: 32

QED Weighted: 0.57

Np Likeness Score: -0.03

References

1. Santra S, Sharma H, Vedachalam S, Antonio T, Reith M, Dutta A..  (2015)  Development of potent dopamine-norepinephrine uptake inhibitors (DNRIs) based on a (2S,4R,5R)-2-benzhydryl-5-((4-methoxybenzyl)amino)tetrahydro-2H-pyran-4-ol molecular template.,  23  (4): [PMID:25593099] [10.1016/j.bmc.2014.12.040]

Source

Source(1):

• Scientific Literature